Payment overview · 2025
General Payments
$40.26
1 reported records · 1 companies
Healthcare provider profile · identity verified
Michael Kevin Burke, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hospice and Palliative Medicine · ALBANY, NY · NPI 1639219744
Verified facts
What the public records show
CMS Open Payments records show Michael Kevin Burke, MD received $40.26 in general payments during 2025 across 1 reported records.
Ethicon US, LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $40.26 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $40.26 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DERMABOND PRINEO Normalized: dermabond prineo |
Device | Ethicon US, LLC | $40.26 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $40.26 | 1 | 2025 |
Source payment records
|
|||||
| PROLENE Normalized: prolene |
Device | Ethicon US, LLC | $40.26 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $40.26 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $40.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 512 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 340 | 56 |
| Gabapentin | Gabapentin | 260 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 247 | 47 |
| Sertraline Hcl | Sertraline Hcl | 228 | 42 |
| Furosemide | Furosemide | 187 | 44 |
| Mirtazapine | Mirtazapine | 180 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 31 |
| Trazodone Hcl | Trazodone Hcl | 145 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 143 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 19 |
| Levetiracetam | Levetiracetam | 104 | 14 |
| Omeprazole | Omeprazole | 104 | 24 |
| Donepezil Hcl | Donepezil Hcl | 100 | 18 |
| Divalproex Sodium | Divalproex Sodium | 95 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 12 |
| Losartan Potassium | Losartan Potassium | 91 | 19 |
| Lisinopril | Lisinopril | 88 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 20 |
| Xarelto | Rivaroxaban | 83 | suppressed |
| Latanoprost | Latanoprost | 81 | 21 |
| Olanzapine | Olanzapine | 81 | 13 |
| Januvia | Sitagliptin Phosphate | 78 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 77 | 76 |
| Atenolol | Atenolol | 77 | 14 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Spironolactone | Spironolactone | 73 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | suppressed |
| Torsemide | Torsemide | 71 | 16 |
| Tramadol Hcl | Tramadol Hcl | 67 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | suppressed |
| Baclofen | Baclofen | 64 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 11 |
| Memantine Hcl | Memantine Hcl | 64 | 13 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Lorazepam | Lorazepam | 63 | 27 |
| Metformin Hcl | Metformin Hcl | 59 | 11 |
| Simvastatin | Simvastatin | 59 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 12 |
| Buspirone Hcl | Buspirone Hcl | 52 | 13 |
| Prednisone | Prednisone | 52 | 14 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Carvedilol | Carvedilol | 47 | 13 |
| Morphine Sulfate | Morphine Sulfate | 45 | 32 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Bumetanide | Bumetanide | 43 | 11 |
| Klor-Con 10 | Potassium Chloride | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 26 |
| Finasteride | Finasteride | 37 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 13 |
| Sucralfate | Sucralfate | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 28 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 25 | 17 |
| Novolog | Insulin Aspart | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | 12 |
| Rytary | Carbidopa/Levodopa | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Cyclosporine | Cyclosporine | 23 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 16 |
| Allopurinol | Allopurinol | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 15 |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40.26 · 1 records | Ethicon US, LLC | DERMABOND PRINEO, ETHICON, PROLENE, STRATAFIX, VISTASEAL | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error